Dexamethasone implants improve visual and anatomical outcomes better than brolucizumab in patients with both DME and hyperreflective intraretinal dots.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback